Matches in Wikidata for { <http://www.wikidata.org/entity/Q90360596> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q90360596 description "article scientifique publié en 2018" @default.
- Q90360596 description "artículu científicu espublizáu n'avientu de 2018" @default.
- Q90360596 description "bài báo khoa học" @default.
- Q90360596 description "scientific article published on 07 December 2018" @default.
- Q90360596 description "wetenschappelijk artikel" @default.
- Q90360596 description "наукова стаття, опублікована в грудні 2018" @default.
- Q90360596 name "SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)" @default.
- Q90360596 name "SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)" @default.
- Q90360596 type Item @default.
- Q90360596 label "SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)" @default.
- Q90360596 label "SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)" @default.
- Q90360596 prefLabel "SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)" @default.
- Q90360596 prefLabel "SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)" @default.
- Q90360596 P1433 Q90360596-C137C1D8-4D83-4BF3-8D01-F3E0429F9AF6 @default.
- Q90360596 P1476 Q90360596-8CD86EA3-BEEF-4A46-9108-0CAD0074D50B @default.
- Q90360596 P2093 Q90360596-0677094D-66B1-4639-90B7-B8099F588ABE @default.
- Q90360596 P2093 Q90360596-23BE2C38-934D-43C7-88AB-F27029BBEBFA @default.
- Q90360596 P2093 Q90360596-2F6E1C4D-AA8D-4F1E-8C1E-5DE7A2DA34E0 @default.
- Q90360596 P2093 Q90360596-40543CDE-1D19-422F-89D0-085FBFCA5252 @default.
- Q90360596 P2093 Q90360596-4A9C09BE-4A83-4489-B15C-CC8200D4FE64 @default.
- Q90360596 P2093 Q90360596-4FFE0500-A91D-4C34-82B7-44C4859AC46C @default.
- Q90360596 P2093 Q90360596-7473AD4E-1D10-42DB-B115-AB75C7AA573C @default.
- Q90360596 P2093 Q90360596-8A55754A-8CF3-4F9B-B777-B219350D290A @default.
- Q90360596 P2093 Q90360596-8C08D35E-F0BB-4A57-B310-457AB563D85D @default.
- Q90360596 P2093 Q90360596-94BCF398-247A-46A9-A760-BB40F1BF2309 @default.
- Q90360596 P2093 Q90360596-9544A1F3-1640-4730-A397-CE35CB3091BA @default.
- Q90360596 P2093 Q90360596-B2D795EE-B1B7-4205-ACC8-4CBA09303751 @default.
- Q90360596 P2093 Q90360596-C10E744D-5F76-4E88-B98C-0E1A93F0E217 @default.
- Q90360596 P2093 Q90360596-CEF6996C-5B9C-4DBE-86C8-C9DCAD948CAB @default.
- Q90360596 P304 Q90360596-638794AD-1953-43B1-A5CC-182159A6D260 @default.
- Q90360596 P31 Q90360596-51F7B278-CD8E-4F8F-B5FE-185863E98B62 @default.
- Q90360596 P356 Q90360596-D2AF8E6E-5A81-4CEE-8CD2-D8965886855C @default.
- Q90360596 P478 Q90360596-1616EF72-DEB0-4F2D-A09C-38DFDF5221E2 @default.
- Q90360596 P50 Q90360596-0C7472B9-99E4-4028-93FC-F71A3B550AE9 @default.
- Q90360596 P50 Q90360596-0E7AAA6A-D401-4F3C-99F7-B94275162D14 @default.
- Q90360596 P50 Q90360596-7436A548-F61B-489A-8C63-78B98DEFBC36 @default.
- Q90360596 P50 Q90360596-8E040738-202C-490B-87AD-3A2E0170054F @default.
- Q90360596 P577 Q90360596-C5BF1B30-1D58-432F-BA1E-BE705EBC8C95 @default.
- Q90360596 P698 Q90360596-676DB3B6-BCCA-4625-9C77-BC88EAA53828 @default.
- Q90360596 P921 Q90360596-6D10A200-6188-4628-8636-28C8FDA1202B @default.
- Q90360596 P921 Q90360596-BF46A05B-CB19-4A0F-9E15-6AF02554E12E @default.
- Q90360596 P356 J.EJCA.2018.11.001 @default.
- Q90360596 P698 30529901 @default.
- Q90360596 P1433 Q332260 @default.
- Q90360596 P1476 "SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)" @default.
- Q90360596 P2093 "Aart Beeker" @default.
- Q90360596 P2093 "Christian Bolenz" @default.
- Q90360596 P2093 "Christian Leiber" @default.
- Q90360596 P2093 "Dogu Teber" @default.
- Q90360596 P2093 "Jan Lehmann" @default.
- Q90360596 P2093 "Jürgen E Gschwend" @default.
- Q90360596 P2093 "Lothar Müller" @default.
- Q90360596 P2093 "Manfred Wirth" @default.
- Q90360596 P2093 "Margitta Retz" @default.
- Q90360596 P2093 "Maria De Santis" @default.
- Q90360596 P2093 "Martin Indorf" @default.
- Q90360596 P2093 "Melanie Frank" @default.
- Q90360596 P2093 "Robbert van Alphen" @default.
- Q90360596 P2093 "Uwe Zimmermann" @default.
- Q90360596 P304 "37-45" @default.
- Q90360596 P31 Q13442814 @default.
- Q90360596 P356 "10.1016/J.EJCA.2018.11.001" @default.
- Q90360596 P478 "107" @default.
- Q90360596 P50 Q1045499 @default.
- Q90360596 P50 Q41700368 @default.
- Q90360596 P50 Q55908299 @default.
- Q90360596 P50 Q79369095 @default.
- Q90360596 P577 "2018-12-07T00:00:00Z" @default.
- Q90360596 P698 "30529901" @default.
- Q90360596 P921 Q1164529 @default.
- Q90360596 P921 Q19000948 @default.